Oramed Pharmaceuticals (ORMP) Net Income towards Common Stockholders (2011 - 2026)

Oramed Pharmaceuticals has reported Net Income towards Common Stockholders for 15 years, with the latest figure at $38.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 601.31% year-over-year to $38.3 million; the trailing twelve-month figure through Mar 2026 stood at $110.0 million (up 488.87% YoY), and the FY2025 full-year result was $64.0 million, up 435.11% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $38.3 million, up from $10.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $48.4 million in Q3 2025, with the low at -$19.6 million in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged $2.9 million across 5 years, with a median of -$3.3 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 800.99% — and 2025, when it slumped 598.17%.
• Oramed Pharmaceuticals' Net Income towards Common Stockholders stood at -$11.7 million in 2022, then surged by 213.95% to $13.3 million in 2023, then slumped by 176.71% to -$10.2 million in 2024, then surged by 198.14% to $10.0 million in 2025, then jumped by 282.76% to $38.3 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $38.3 million (Q1 2026), $10.0 million (Q4 2025), and $48.4 million (Q3 2025), per Business Quant data.